2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF

Abstract: 2,3,4,5-Tetrahydro-1H-3-benzazepines having general formula (I) wherein R<1> is Cl or Br; R<3> and R<4> are hydrogen, halogen, CF3, CN, NO2, or NH2. The compounds are useful in treatment of certain disorders in the central nervous system.

Description: 2,3 ,4, 5-tetrahydro-lH-3-benzazepines and pharmaceutically acceptable acid addition salts thereof. This invention relates to novel 2,3,4,5-tetrahydro-1 H-3-benzazepines and pharmaceutically acceptable acid addition salts thereof, to methods for their preparation, to pharmaceutical compositions containing them, and to their use in the treatment of certain disorders in the central nervous system, e.g., psychosis, pain, depression, sleep disturbances, dyskinesias, Parkinson's disease, stroke. In the last decade intensive pharmacological research concerning benz- azepines has taken place. The pharmacological properties of benzazepines depend to a large extent on the substituents. Various substituted benz¬ azepines exhibiting neuroleptic, anti-aggressive, anti-Parkinson and vascular effects are known. In European Patent No. 0 200 455 (Novo Industri A/S) 2,3,4,5-tetrahydro- 1 H-3-benzazepines having a heterocyclic or an ortho-fused heterocyclic ringsystem in the 5-position are described. These compounds are claimed to have antipsychotic and antidepressive effects. It has now been found that a group of 5'- or 6'-substituted or 5',6'-di- substituted (2,3-dihydrobenzofuran-7-yl)-2,3,4,5-tetrahydro-1 H-3-benzazepi- ne compounds exhibit strong antidopaminergic effect which makes them useful in psychopharmaceutical applications. Surprisingly, the compounds of the invention exhibit unexpectedly high oral antidopaminergic activity compared to known compounds. According to the present invention there are provided 2,3,4,5-tetrahydro-1 H- 3-benzazepines of the general formula I wherein R 1 is Cl or Br; R 3 and R 4 independently are hydrogen, halogen, CF 3 , CN, N0 2 or NH 2 and pharmaceutically acceptable acid addition salts thereof, provided that R 3 and R 4 cannot be hydrogen at the same time. Specific compounds of formula (I) are: (+) 8-chloro-5-(5-bromo-2,3-dihydrobenzofuran-7-yl)-7-hydroxy-3-methyl- 2,3,4,5-tetrahydro-1H-3-benzazepine, (+) 8-chloro-5-(2,3-dihydro-5-iodo-benzofuran-7-yl)-7-hydroxy-3-methyl- 2,3,4,5-tetrahydro-1H-3-benzazepine, (+)8-chloro-5-(5,6-dichloro-2,3-dihydrobenzofuran-7-yl)-7-hydroxy-3-methyl- 2 f 3,4,5-tetrahydro-1 H-3-benzazepine, (+)8-chloro-5-(5-chloro-2,3-dihydrobenzofuran-7-yl)-7-hydroxy-3-methyl- 2,3,4,5-tetrahydro-1H-3-benzazepine, 8-chloro-5-(5-nitro-2,3-dihydrobenzofuran-7-yI)-7-hydroxy-3-methyl-2,3,4,5- tetrahydro-1 H-3-benzazepine, 8-chloro-5-(5-amino-2,3-dihydrobenzofuran-7-yl)-7-hydroxy-3-methyl-2,3,4,5- tetrahydro-1 H-3-benzazepine The compounds of formula I may be presented as a mixture of enantio- mers, which may be resolved into the individual pure enantiomers. This resolution may conveniently be performed by fractional crystallization from various solvents, of the salts of compounds of the formula I with optical active acids or by other methods known from the literature, e.g. chiral column chromatography. Therefore, this invention includes all isomers, whether resolved or mixtures thereof. Particularly valuable embodiments of this invention are non-toxic, pharma¬ ceutically acceptable acid addition salts of benzazepines of formula I. Such salts include those derived from inorganic and organic acids such as hydrochloric, hydrobromic, sulphuric, phosphoric, methanesulfonic, acetic, lactic, maleic, phthaiic and tartaric acids. These salts may be prepared by methods known to professionals skilled in the art. The invention also relates to compounds of formula I, wherein R 3 or R 4 is a radioactive isotope of iodine or bromine, such as the clinically used iso¬ topes, 122 l, 123 l, 125 l, 131 l, ^Br, 82 Br and 76 Br. These compounds have been found useful as imaging agents in Single Photon Emission Computed Tomography (SPECT) or in Positron Emission Tomography (PET). The invention further provides pharmaceutical compositions comprising the compounds of the invention. The dosage formulation will preferably contain the active compounds in the range of 0.1 mg to about 1000 mg for oral dosing. Typical dosage for antipsychotic effect would vary between about 0.5 to 10 mg/kg per day divided in 2 or 3 doses, administered orally. The compounds of the present invention can be prepared by various methods. These methods comprise: a) halogenation of a compound of formula II wherein R 1 is defined as above and R 2 is O-C^-alkyl or O-CO-C^-alkyl to form a compound of the general formula III wherein R 1 and R 2 are defined as above, R 3 is halogen or H, R 4 is halogen, and deacylation or dealkylation of a compound of formula III to form a compound of formula i; wherein R 1 , R 3 and R 4 are defined as above, b) nitration of a compound of formula as defined in a) to form a compound of the general formula wherein R 1 and R 2 are defined as in a), R 3 is H and R 4 is -N0 2 , and deacy¬ lation or dealkylation of a compound of formula III to form a compound of formula I, wherein R 1 , R 3 and R 4 are as defined above or c) reduction or catalytic hydrogenation of a compound of formula IV, (IV) wherein R 1 is defined as above, R 2 is O-C^-alkyl or O-CO-C^-alkyl and R 3 is H, to a compound of formula III, wherein R 1 , R 2 and R 3 are defined as above and R 4 is -NH 2 , and deacylation or dealkylation of the compound of formula III to form a compound of formula I, wherein R 1 , R 3 and R 4 are defined as above. The starting materials employed in the synthesis of the compounds of formula I are known e.g. from European Patent No. EP 0.200.455. The compounds of the invention are useful because of their pharmacologi- cal activity. In particular, the compounds of the invention are active in assays predictive for antipsychotic effect. Thus the compounds of formula I were tested for their binding to dopamine D 1 receptor in homogenates from rat striatum using the method described (Life Science vol. 37, p. 1971 (1985) P. Andersen et al.) and the result appears from Table I. IC^, is the affinity of tested compounds for the dopamine D 1 receptor. TABLE Test Compound IC„ (nM) Dopamine D 1 receptor Example No. 1 0.7 Example No. 3 0.9 The previously mentioned high oral antidopaminergic activity of the com¬ pounds of the present invention in comparison to known compounds without the claimed 5'-substituents or β'-substituents (EP 200.455) can be shown by calculating the ratio between oral ability to inhibit stereotyped be¬ haviour in mouse following methylphenidate (i.e., Acta Pharmacol. Toxicol. 31, 1972, 488) and inhibition of 3 H-SCH 23390 binding in vitro (measure of D^receptor antagonism). This yielded the following ratios: Test Compound Index of oral mg/kg / IC g o SCH 23390 binding Example no. 1 4 Example no. 3 1.6 Example no. 5 in EP 200.455 23 The compound of the invention, together with a conventional adjuvant, carrier, or diluent, and if desired in the form of a pharmaceutically accept¬ able acid addition salt thereof, may be placed into the form of pharmaceuti¬ cal compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids, such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form or sterile injectable solutions for parenteral (including subcutane¬ ous) use. Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective central nervous system ailment alleviating amount of the active ingredient commensurate with the intended daily dosage range to be employed. Tablets containing 0.1-1000 mg of active ingredient or, more specified 0.5-10 mg, per tablet, are accordingly suitable representative unit dosage forms. The compounds of this invention can thus be used for the formulation of pharmaceutical preparations, e.g., for oral and parenteral administration to mammals including humans, in accordance with conventional methods of galenic pharmacy. Conventional excipients are such pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral or oral application which do not deleteriously react with the active compound. Examples of such carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, syrup, peanut oil, olive oil, gelatin, lactose, terra alba, sucrose, agar, pectin, acacia, amylose, magne¬ sium stearate, talc, silicic acid, stearic acid, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxymethylcellulose and polyvinylpyrrolidone. The pharmaceutical preparations can be sterilized and mixed, if desired, with auxiliary agents, such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or colouring substances and the like, which do not deleteriously react with the active compound. For parenteral application, particularly suitable are injectable solutions or suspensions, preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil. Ampoules are convenient unit dosage forms. For oral administration, particularly suitable are tablets, dragees, or cap¬ sules having talc and/or a carbohydrate carrier or binder or the like, the carrier preferably being lactose and/or corn starch and/or potato starch. A syrup, elixir or like can be used when a sweetened vehicle can be employed. Generally, as to broader ranges, the compounds of the invention are dispensed in unit dosage form comprising 0.05-100 mg in a pharma¬ ceutically acceptable carrier per unit dosage. A typical tablet, which may be prepared by conventional tabletting tech- niques, contains: Active compound 1.0 mg Lactosum 67.8 mg Ph.Eur. Avicel® 31.4 mg Amberlite® IRP 88 1.0 mg Magnesii stearas 0.25 mg Ph.Eur. The following examples illustrate the preparation of the novel compounds of this invention: EXAMPLE 1 (+) 8-Chloro-5-(5-bromo-2,3-dihydrobenzofuran-7-yl)-7-hydroxy-3-methyl- 2,3,4,5-tetrahydro-1 H-3-beπzazepine ; a) (+) 8-Chloro-5-(2,3-dihydrobenzofuran-7-yl)-7-methoxy-3-methyl- 2,3,4,5-tetrahydro-1 H-3-benzazepine (1.0 g, 2.9 mmol) was dissolved in acetic acid (10 ml). To the stirred solution was added bromine (0.20 ml, 4.0 mmol) in acetic acid (5 ml) over a period of 2 h. The mixture was stirred overnight at room temperature. A precipitate was formed. The white solid was filtered and washed with diethylether. Yield 1.1 g (75%) of (+) 8-chloro-5-(5-bromo-2,3-dihydrobenzufuran-7-yl)-7- methoxy-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, HBr as a white crystalline powder. NMR 200 MHz 1 H-chemical shifts in ppm of the free base. CDCI 3 as solvent, TMS as internal standard. [5, ppm]: 2.42 (s,3H), 2.40-2.55 (m,1H), 2.95 (m,5H), 3.28 (t,2H), 3.70 (s,3H), 4.43 (d,1H), 4.58 (t,2H), 6.38 (s,1H), 6.98 (d,1H), 7.18 (s,1H), 7.26 ( ,1H). b) (+) 8-Chloro-5-(5-bromo-2,3-dihydrobenzofuran-7-yl)-7-methoxy-3- methyl-2,3,4,5-tetrahydro-1 H-3-benzazepine (3.9 g, 9.2 mmol) was dissolved in dichloromethane (50 ml). The solution was cooled on an icebath. To the stirred solution was added 10 vol % BBr 3 in dichloromethane (14 ml, 14.8 mmol). The reaction mixture was stirred for 2 h, and then warmed to room temperature. The mixture was added methanol and concentrated at reduc¬ ed pressure. Methanol was added (50 ml) and the mixture was refluxed for 2 h, and then stirred at room temperature overnight. The mixture was con¬ centrated to a thick oil. Methanol (15 ml) was added and under stirring NaOH (0.5 M) was added until precipitation started. The mixture was stirred for one hour, then cooled on an icebath. The brown solid was filtered and washed with water. Yield 3.2 g (85%) of the title compound as a crystalline slightly brown powder. NMR 200 MHz 1 H-chemical shifts in ppm. of the free base. CDCI 3 as solvent, TMS as internal standard. [δ, ppm]: 2.25 (t,1 H), 2.35 (s,3H), 2.90 (m,5H), 3.22 (t,2H), 4.35 (d,1 H), 4.51 (t,2H), 6.30 (s,1 H), 6.96 (d,1 H), 7.10 (s,1 H), 7.22 (d,1 H). EXAMPLE 2 (+) 8-Chloro-5-(2,3-dihydro-5-iodo-benzofuran-7-yl)-7-hydroxy-3-methyl- 2,3,4,5-tetrahydro-1 H-3-benzazepine a) Iodine (4.2 g, 16.3 mmol) and 32% peracetic acid (10.3 ml, 49 mmol) was stirred in acetic acid (50 ml) for 15 min. at room temperature. (+) 8-Chloro-5-(2,3-dihydrobenzofuran-7-yl)-7-methoxy-3-methyl-2,3,4,5- tetrahydro-1 H-3-benzazepine (5.6 g, 16.3 mmol) in acetic acid (50 ml) was added to the mixture over a period of 1 h. The mixture was stirred for additional 3 h. The mixture was treated with sodium thiosulfate and eva¬ porated under reduced pressure to a brown solid. Dichloromethane was added and the organic phase was washed with water, NaOH (aq), water and then dried over anhydrous magnesium sulfate. The extract was filtered and concentrated to a brown solid. The product was purified by column chromatography (silica gel: CH 2 CI 2 -MeOH). Yield: 4.8 g (63%) of (+) 8-chloro-5-(2,3-dihydro-5-iodo-benzofuran-7-yl)-7- methoxy-3-methyl-2,3,4,5-tetrahydro-1 H-3-benzazepine as a crystalline slightly brown powder. NMR 200 MHz 1 H-chemical shifts in ppm of the free base. CDCI 3 as solvent, TMS as internal standard. [δ, ppm]: 2.32 (m,1H), 2.36 (s,3H), 2.92 (m,5H), 3.22 (t,2H), 3.70 (s,3H), 4.37 (dd,1H), 4.52 (t,2H), 6.35 (s,1H), 7.13 (broad s,2H), 7.42 (d,1 H). b. (+) 8-chloro-5-(2,3-dihydro-5-iodo-benzofuran-7-yl)-7-methoxy-3- methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (300 mg, 0.65 mmol) was dissolved in dichloromethane (15 ml). To the stirred solution was added 10% BBr 3 in dichloromethane (2.0 ml, 2.1 mmol) over a period of 1 h. The mixture was stirred at room temperature for additionally 15 min. The mixture was diluted with methanol (25 ml) and concentrated at reduced pressure. Methanol (20 ml) was added, and under stirring NaOH (0.5 M) was added until pH 7. The mixture was stirred for 1 h and water was added until precipitation started. The solid was filtered and washed with water. Yield: 207 mg (70%) of the title compound as a crystalline slightly brown powder. NMR 200 MHz 1 H-chemical shifts in ppm of the free base. CDCI 3 as solvent, TMS as internal standard. (δ, ppm): 2.28 (t,1H), 2.38 (s,3H), 2.90 (m,5H), 3.22 (t,2H), 4.37 (d,1 H), 4.52 (t,2H), 6.30 (s,1H), 7.10 (s,1 H), 7.18 (d,1H), 7.40 (d,1 H). EXAMPLE 3 (+)8-Chloro-5-(5,6-dichloro-2,3-dihydrobenzofuran-7-yl)-7-hydroxy-3-methyl- 2,3,4,5-tetrahydro-1H-3-benzazepine 1.65 g (0.005 mole) (+)8-chloro-5-(2,3-dihydrobenzofuran-7-yi)-7-hydroxy-3- methyl-2,3,4,5-tetrahydro-1 H-3-benzazepine was dissolved in 2.5 ml acetic anhydride and left at room temperature for 1 h. The clear solution was concentrated in vacuo and repeatedly stripped with glacial acetic acid. Then the residue was redissolved in 10 ml acetic acid and 7.2 ml (0.0055 mole) of a 0.77 molar solution of chlorine in glacial acetic acid was slowly added to the stirred solution at room temperature. After 1 h another 7.1 ml of the chlorine solution was added. The reaction mixture was again stirred for 1 h. Then 20 ml ethanol and 1 ml concentrated HCI were added, and the mixture was refluxed for 1 h. After cooling, the solution was diluted with 20 ml ethanol and adjusted to pH 8 by careful addition of 10% Na 2 C0 3 solu¬ tion. The crude product precipitated out spontaneously and was collected by filtration. Column chromatography (stationary phase: C18 silica; eluent: ammoniumsulfate/acetonitrile 70:30; pH 3.3) yielded the pure title com¬ pound. M.p.: 224-225°C. 1 H-NMR in CDCI 3 [δ, ppm]: 2.23 (t,1H); 2.40 (s,3H); 2.73 (dd,1H); 2.80-3.37 (m,6H); 4.57 (t,2H); 4.93 (d,1H); 6.17 (broad s,1H); 7.07 (s,1 H); 7.25 (s,2H). EXAMPLE 4 (+)8-Chloro-5-(5-chloro-2,3-dihydrobenzofuran-7-yl)-7-hydroxy-3-methyl- 2,3,4,5-tetrahydro-1H-3-benzazepine The synthesis and workup followed essentially the method described in example 3, with the only difference that 1.1 equivalent of chlorine was used for the chlorination. The crude product was chromatographically purified as described above and yielded the free base as a crystalline powder. M.p.: 182-186°C. 1 H-NMR in CDCI 3 [δ, ppm] 2.40 (s,3H); 2.30-3.20 (m,8H); 3.90 (dd,1 H); 4.15 (t,2H); 5.96 (s,1H); 6.40 (d,1H); 6.65 (s,1H); 6.70 (d,1H). EXAMPLE 5 8-Chloro-5-(5-nitro-2,3-dihydrobenzofuran-7-yl)-7-hydroxy-3-methyl-2,3,4,5- tetrahydro-1 H-3-benzazepine a) 1.50 g (0.00386 mole) 8-chloro-5-(2,3-dihydrobenzofuran-7-yl)-7- methoxy-3-methyl-2,3,4,5-tetrahydro-1 H-3-benzazepine was dissolved in 20 ml acetic acid. 2.80 g (0.0116 mole) copper nitrate trihydrate was added and the mixture was stirred at room temperature for 18 h. The solvent was evaporated in vacuo, the residue treated with aqueous ammonia and extracted with dichloromethane. The solution was washed with water and brine, concentrated in vacuo and the residue redissolved in ether. Unso- luble impurities were removed by filtration and 8-chloro-5-(5-nitro-2,3- dihydrobenzofuran-7-yl)-7-methoxy-3-methyl-2,3 I 4,5-tetrahydro-1 H-3-ben- zazepine was obtained as the hydrochloride by adding an excess of a HCI solution in ether and collecting the precipitate by filtration. White crystals. M.p.: 251-254°C. 1 H-NMR of the free base in CDCI 3 [δ, ppm]: 2.37 (s,3H); 2.40-3.25 (m,6H); 3.34 (t,2H); 3.70 (s,3H); 4.45 (d,1H); 4.73 (t,2H); 6.36 (s,1 H); 7.20 (s,1 H); 7.86 (d,1H); 8.03 (d,1H). b) 0.220 g (0.00052 mole) 8-chloro-5-(5-nitro-2,3-dihydrobenzofuran-7- yl)-7-methoxy-3-methyl-2,3,4,5-tetrahydro-1 H-3-benzazepine hydrochloride was dissolved in 10 ml dry dichloromethane and cooled in an ice bath. To the stirred solution 5 ml of a 1 molar solution of boron trichloride in hexane was added. The reaction mixture was allowed to warm up to room tempera¬ ture and was stirred for 4.5 h. Then the solution was cooled in an ice bath and hydrolized by carefully adding 15 ml methanol. The formed crystalline hydrochloride of the title compound was collected by filtration and dried. Slightly pink crystalline powder. M.p.: 265-270°C under decomposition. 1 H-NMR in d 6 -DMSO [δ, ppm]: 2.80 (d,3H); 2.85-3.85 (m,8H); 4.75 (t,2H); 4.90 (d,1 H); 6.22 (s,1 H); 7.27 (s,1 H); 8.02 (d,1 H); 8.25 (d,1 H); 9.95 (s,1 H); 11.30 (broad s,1 H). EXAMPLE 6 8-Chloro-5-(5-amino-2,3-dihydrobenzofuran-7-yl)-7-hydroxy-3-methyl-2,3,4,5- tetrahydro-1 H-3-benzazepine a) A stirred mixture of 2.50 g (0.011 mole) sodium sulfide and 0.60 g (0.011 mole) ammonium chloride in 10 ml n-propanol was warmed to reflux temperature and a solution of 0.44 g (0.0011 mole) 8-chloro-5-(5-nitro-2,3- dihydrobenzofuran-7-yl)-7-methoxy-3-methyl-2,3,4,5-tetrahydro-1 H-3-benz- azepine was added dropwise and reflux was continued for 16 h. The solvent was removed in vacuo and the residue was redissolved in dichlo¬ romethane. The solution was washed with 0.1 N NaOH, water and brine. Evaporation yielded 8-chloro-5-(5-amino-2,3-dihydrobenzofuran-7-yl)-7- methoxy-3-methyl-2,3,4,5-tetrahydro-1 H-3-benzazepine as a foam. 1 H-NMR in CDCI 3 [δ, ppm]: 2.37 (s,3H + m,1 H); 2.75-3.30 (m,7H); 3.35 (broad s,2H); 3.68 (s,3H); 4.33 (t,1 H); 4.46 (t,2H); 6.21 (d,1 H); 6.43 (s,1 H); 6.53 (d,1 H); 7.12 (s,1 H). b) 2.8 ml (0.0056 mole) of a 2M solution of boron trichloride in di¬ chloromethane was added to an icecold stirred solution of 200 mg (0.00056 mole) of the product of step a. in 10 ml dichloromethane. The reaction mixture was stirred for 8 h at room temperature and was then concentrated in vacuo. The residue was redissolved in ether, washed with saturated NaHC0 3 -solution, water and brine and dried over Na^O^ Precipitation with a solution of HCI in ether yielded the title compound as the hydrochloride. M.p.: 241-244°C. 1 H-NMR in d 6 -DMS0 [δ, ppm]: 2.80 (s,3H); 3.00 (m,2H); 3.31 (t,2H); 3.35- 3.67 (m,4H); 4.60 (t,2H); 4.77 (d,1 H); 6.23 (s,1 H); 6.98 (s,1 H); 7.26 (s,1 H); 7.33 (s,1 H); 10.00 (s,1H); 10.25 (broad s,2H); 10.00 (s,1 H).

Claims: CLAIMS 1. 2,3,4,5-tetrahydro-1 H-3-benzazepines having the general formula I wherein R 1 is Cl or Br; R 3 and R 4 independently are hydrogen, halogen, CF 3 , CN, N0 2 or NH 2 and pharmaceutically acceptable acid addition salts thereof, provided that R 3 and R 4 cannot be hydrogen at the same time. 2. Compounds according to claim 1 wherein R 1 is Cl. 3. A compound according to claim 1 which is (+)-8-chloro-5-(5-bromo- 2,3-dihydrobenzofuran-7-yl)-7-hydroxy-3-methyl-2,3,4,5-tetrahydro-1 H-3- benzazepine, (+)-8-chloro-5(2,3-dihydro-5-iodo-benzofuran-7-yl)-7-hydroxy-3-methyl- 2,3,4,5-tetrahydro-1 H-3-benzazepine, (+) 8-chloro-5(5,6-dichloro-2,3-dihydrobenzofuran-7-yl)-7-hydroxy-3-methyl- 2,3,4,5-tetrahydro-1 H-3-benzazepine, (+) 8-chloro-5(5-chloro-2,3-dihydrobenzofuran-7-yl)-7-hydroxy-3-methyl- 2,3,4,5-tetrahydro-1 H-3-benzazepine, 8-chloro-5(5-nitro-2,3-dihydrobenzofuran-7-yl)-7-hydroxy-3-methyl-2,3,4,5- tetrahydro-1 H-3-benzazepine or 8-chloro-5(5-amino-2,3-dihydrobenzofuran-7-yl)-7-hydroxy-3-methyl-2,3,4,5- tetrahydro-1 H-3-benzazepine. A pharmaceutical composition comprising a compound according to claims 1-3 or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent. 5;. A pharmaceutical composition suitable for use in the treatment of a central nervous system ailment comprising a compound according to claims 1-3 together with a pharmaceutically acceptable carrier or diluent. ( A pharmaceutical composition according to claim 4 or 5 wherein it is in the form of an oral dosage unit containing 0.1-100 mg of the active compound. 7_ Use of a compound according to claims 1-3 for producing a pharmaceutical composition for the treatment of an indication related to a central nervous system ailment. A method of treating a central nervous system ailment in a person in need of such treatment characterized in administering to said person an amount of a compound according to claims 1-3 effective in alleviation of such an ailment. 9. A method of treating a central nervous system ailment in a subject in need of such treatment comprising the step of administering to said subject an amount of a compound according to claims 1-3, which is effective for the alleviation of such ailment in the form of a pharmaceutical composition thereof, in which it is present together with a pharmaceutically acceptable carrier or diluent. 10. A method for the preparation of a compound according to claim 1 , characterized in a) halogenation of a compound of formula II wherein R 1 is defined as above and R 2 is 0-C M -alkyl or O-CO-C^-alkyl to form a compound of the general formula III wherein R 1 and R 2 are defined as above, R 3 is halogen or H, R 4 is halogen, and deacylation or dealkylation of a compound of formula III to form a compound of formula I, wherein R 1 , R 3 and R 4 are defined as above, b) nitration of a compound of formula II as defined in a) to form a compound of the general formula III, wherein R 1 and R 2 are defined as in a), R 3 is H and R 4 is -N0 2 , and deacy¬ lation or dealkylation of a compound of formula III to form a compound of formula I, wherein R 1 , R 3 and R 4 are as defined above or c) reduction or catalytic hydrogenation of a compound of formula IV, (IV) wherein R 1 is defined as above, R 2 is O-C^-alkyl or O-CO-C^-alkyl and R 3 is H, to a compound of formula III, wherein R 1 ? R 2 and R 3 are defined as above and R 4 is -NH 2 , and deacylation or dealkylation of the compound of formula III to form a compound of formula I, wherein R 1 , R 3 and R 4 are defined as above.

Inventors: FOGED CHRISTIAN, HOHLWEG ROLF, NIELSEN ERIK BARDRUM, FOGED, CHRISTIAN, HOHLWEG, ROLF, NIELSEN, ERIK, BARDRUM
Applicants: NOVONORDISK AS, NOVO NORDISK A/S
Application year: 1993
Main classification: A61K31
IPC codes: A61K31, A61P25, C07D405